Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novartis Ag ADR (NVS)

Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 200,111,456
  • Shares Outstanding, K 2,119,600
  • Annual Sales, $ 46,660 M
  • Annual Income, $ 14,850 M
  • 60-Month Beta 0.54
  • Price/Sales 4.36
  • Price/Cash Flow 8.73
  • Price/Book 4.24
Trade NVS with:

Options Overview Details

View History
  • Implied Volatility 24.96% ( +0.64%)
  • Historical Volatility 16.25%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 24.96% on 04/16/24
  • IV Low 12.92% on 12/05/23
  • Put/Call Vol Ratio 0.14
  • Today's Volume 6,558
  • Volume Avg (30-Day) 2,634
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 62,010
  • Open Int (30-Day) 47,050

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 1.73
  • Number of Estimates 3
  • High Estimate 1.77
  • Low Estimate 1.70
  • Prior Year 1.71
  • Growth Rate Est. (year over year) +1.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.64 +0.60%
on 04/16/24
98.21 -5.10%
on 04/04/24
-4.07 (-4.18%)
since 03/15/24
3-Month
92.64 +0.60%
on 04/16/24
108.78 -14.32%
on 01/22/24
-14.49 (-13.46%)
since 01/16/24
52-Week
92.19 +1.10%
on 10/27/23
108.78 -14.32%
on 01/22/24
-4.68 (-4.78%)
since 04/14/23

Most Recent Stories

More News
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.

Think globally with this high-yielding ETF.

TM : 236.52 (-2.13%)
NVS : 93.20 (-1.28%)
HSBC : 39.65 (-2.27%)
SHEL : 71.06 (-1.22%)
RHHBY : 30.2300 (-1.14%)
VYMI : 66.16 (-1.46%)
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024

Stocks that traded heavily or had substantial price changes on Thursday: Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise

ALPN : 64.50 (+0.12%)
CONN : 3.85 (-3.02%)
NTIC : 14.89 (+0.13%)
BTUUQ : 1.1924 (+211.33%)
BTU : 24.09 (+5.01%)
NVS : 93.20 (-1.28%)
KMX : 69.80 (+0.49%)
FAST : 68.79 (-0.86%)
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster...

AZN : 68.26 (-0.68%)
FUSN : 21.26 (-0.09%)
NVS : 93.20 (-1.28%)
LLY : 746.74 (-0.54%)
BMY : 48.26 (-0.52%)
Health Canada grants approval of the Eye-Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS) for use in tracking disease progression in people living with MS

More than 90,000 Canadians—or one in 400 people across Canada—live with multiple sclerosis (MS),1 a neurodegenerative, chronic condition that affects the...

NVS : 93.20 (-1.28%)
1 Magnificent Dividend Stock to Buy and Hold

The company's business went through some important changes last year.

NVS : 93.20 (-1.28%)
Novartis Canada's statement on CADTH draft recommendations for LEQVIO® (inclisiran)

/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee...

NVS : 93.20 (-1.28%)
Biotech Sector Advances in Pancreatic Cancer Research

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 21.03 (-0.99%)
ONCY : 1.0800 (+1.89%)
ONC.TO : 1.47 (+0.68%)
NVS : 93.20 (-1.28%)
IBRX : 4.92 (-6.11%)
ACRS : 1.2200 (+0.83%)
NUVB : 2.81 (-2.43%)
Biotech’s Role in Addressing the Pancreatic Cancer Emergency

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

NVX : 2.57 (-1.15%)
ONCY : 1.0800 (+1.89%)
ONC.TO : 1.47 (+0.68%)
NVS : 93.20 (-1.28%)
IBRX : 4.92 (-6.11%)
ACRS : 1.2200 (+0.83%)
NUVB : 2.81 (-2.43%)
3 Dividend Stocks to Buy Hand Over Fist in March

Income investors might want to load up on these great dividend stocks.

GILD : 67.31 (-0.65%)
NVS : 93.20 (-1.28%)
PFE : 25.69 (-0.85%)
Beyond the GRANOLAS: JPMorgan Picks 3 Top Stocks to Bet on Europe

The renowned brokerage firm weighed in on its top stock picks from the European market, which could offer investors better value than the outsized GRANOLAS group of equities at current levels.

NVDA : 874.15 (+1.64%)
MSFT : 414.58 (+0.23%)
AMZN : 183.32 (-0.16%)
AAPL : 169.38 (-1.92%)
META : 499.76 (-0.09%)
GOOGL : 154.40 (-0.30%)
TSLA : 157.11 (-2.71%)
GS : 396.86 (-1.00%)
GSK : 39.95 (-1.36%)
RHHBY : 30.2300 (-1.14%)
NSRGY : 100.8300 (-0.12%)
NVS : 93.20 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy,...

See More

Key Turning Points

3rd Resistance Point 94.23
2nd Resistance Point 93.80
1st Resistance Point 93.50
Last Price 93.20
1st Support Level 92.77
2nd Support Level 92.34
3rd Support Level 92.04

See More

52-Week High 108.78
Fibonacci 61.8% 102.44
Fibonacci 50% 100.49
Fibonacci 38.2% 98.53
Last Price 93.20
52-Week Low 92.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar